Legal Affairs

Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Federal rescheduling under President Trump’s Executive Order sparked widespread state reactions and investor outlooks into early 2026, blending consolidations and expansions with regulatory friction, outright manipulation, and overtures to public opinion. Psychedelics ...

Kenyan MP Advocates for Regulated Cannabis Framework

NAIROBI – Peter Kalerwa Salasya, the outspoken member of Parliament for Kenya's Mumias East constituency, has ignited fresh debate on Сannabis policy by urging the government to pursue legalization under strict controls. Salasya highlighted the ...

Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Federal rescheduling under President Trump’s Executive Order sparked widespread state reactions and investor outlooks into early 2026, blending consolidations and expansions with regulatory friction, outright manipulation, and overtures to public opinion. Psychedelics ...

Medical Cannabis: Growth and Investment in 2024

LOS ANGELES- The medical cannabis industry is navigating 2024 with key players like Grow Group and Somai Pharmaceuticals leveraging new regulations and market dynamics to achieve ambitious growth targets. This article examines the recent developments ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands (NYSE: STZ), maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal ...

Critics Slam Thai Government’s Approach to Cannabis

LOS ANGELES- Critics have strongly opposed the Thai government's plan to reclassify cannabis as a narcotic, arguing that it will harm businesses involved in cannabis-based products and undermine investor confidence in the country. On July ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands,  maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal year 2025 ...

Subscribe To Our Newsletter